TY - JOUR
T1 - Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment
AU - Loureiro, Liliana R.
AU - Hoffmann, Lydia
AU - Neuber, Christin
AU - Rupp, Luise
AU - Arndt, Claudia
AU - Kegler, Alexandra
AU - Kubeil, Manja
AU - Hagemeyer, Christoph E.
AU - Stephan, Holger
AU - Schmitz, Marc
AU - Feldmann, Anja
AU - Bachmann, Michael
N1 - Funding Information:
Open Access funding enabled and organized by Projekt DEAL. This research was funded by Helmholtz Initiative and Networking Fund (Radio-Immuno-Theranostics (MHELTHERA), project ID: InterLabs-0031) granted to MB by the Helmholtz International Lab MHELTHERA and the Federal Ministry of Education and Research (BMBF) (03ZU1111LA to AF and 03ZU1111LB to MB and MS). CA is a fellow of the Mildred Scheel Early Career Center Dresden P funded by the German Cancer Aid (Deutsche Krebshilfe). 2
Funding Information:
We would like to greatly acknowledge Annegret Riedel, Luisa Zimmermann, Andrea Suhr, Kim Weiße and Katja Peter for their excellent technical support. We thank Prof. Dr. Martin Bornhäuser and Dr. Manja Wobus (Department of Medicine 1, University Hospital Carl Gustav Carus, TU Dresden) for kindly providing the SCP-1 cell line. We also thank Prof. Dr. Torsten Tonn (German Red Cross Blood Donation, Dresden) for providing buffy coats of healthy donors.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Background: Chimeric antigen receptor (CAR) T-cells are a promising approach in cancer immunotherapy, particularly for treating hematologic malignancies. Yet, their effectiveness is limited when tackling solid tumors, where immune cell infiltration and immunosuppressive tumor microenvironments (TME) are major hurdles. Fibroblast activation protein (FAP) is highly expressed on cancer-associated fibroblasts (CAFs) and various tumor cells, playing an important role in tumor growth and immunosuppression. Aiming to modulate the TME with increased clinical safety and effectiveness, we developed novel small and size-extended immunotheranostic UniCAR target modules (TMs) targeting FAP. Methods: The specific binding and functionality of the αFAP-scFv TM and the size-extended αFAP-IgG4 TM were assessed using 2D and 3D in vitro models as well as in vivo. Their specific tumor accumulation and diagnostic potential were evaluated using PET studies after functionalization with a chelator and suitable radionuclide. Results: The αFAP-scFv and -IgG4 TMs effectively and specifically redirected UniCAR T-cells using 2D, 3D, and in vivo models. Moreover, a remarkably high and specific accumulation of radiolabeled FAP-targeting TMs at the tumor site of xenograft mouse models was observed. Conclusions: These findings demonstrate that the novel αFAP TMs are promising immunotheranostic tools to foster cancer imaging and treatment, paving the way for a more convenient, individualized, and safer treatment of cancer patients. Graphical Abstract: [Figure not available: see fulltext.]
AB - Background: Chimeric antigen receptor (CAR) T-cells are a promising approach in cancer immunotherapy, particularly for treating hematologic malignancies. Yet, their effectiveness is limited when tackling solid tumors, where immune cell infiltration and immunosuppressive tumor microenvironments (TME) are major hurdles. Fibroblast activation protein (FAP) is highly expressed on cancer-associated fibroblasts (CAFs) and various tumor cells, playing an important role in tumor growth and immunosuppression. Aiming to modulate the TME with increased clinical safety and effectiveness, we developed novel small and size-extended immunotheranostic UniCAR target modules (TMs) targeting FAP. Methods: The specific binding and functionality of the αFAP-scFv TM and the size-extended αFAP-IgG4 TM were assessed using 2D and 3D in vitro models as well as in vivo. Their specific tumor accumulation and diagnostic potential were evaluated using PET studies after functionalization with a chelator and suitable radionuclide. Results: The αFAP-scFv and -IgG4 TMs effectively and specifically redirected UniCAR T-cells using 2D, 3D, and in vivo models. Moreover, a remarkably high and specific accumulation of radiolabeled FAP-targeting TMs at the tumor site of xenograft mouse models was observed. Conclusions: These findings demonstrate that the novel αFAP TMs are promising immunotheranostic tools to foster cancer imaging and treatment, paving the way for a more convenient, individualized, and safer treatment of cancer patients. Graphical Abstract: [Figure not available: see fulltext.]
KW - 3D in vitro models
KW - Cancer immunotherapy
KW - Fibroblast activation protein (FAP)
KW - Immunotheranostic Target Modules (TMs)
KW - Tumor microenvironment (TME)
KW - UniCAR T-cells
UR - http://www.scopus.com/inward/record.url?scp=85179673881&partnerID=8YFLogxK
U2 - 10.1186/s13046-023-02912-w
DO - 10.1186/s13046-023-02912-w
M3 - Article
C2 - 38102692
AN - SCOPUS:85179673881
SN - 1756-9966
VL - 42
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
IS - 1
M1 - 341
ER -